SC

SCM Lifescience Co., Ltd.

Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.

298060 | KO

Overview

Corporate Details

ISIN(s):
KR7298060005
LEI:
Country:
South Korea
Address:
인천광역시 연수구 갯벌로145번길 7-7 (송도동, 에스씨엠생명과학(주)), 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SCM Lifescience Co., Ltd. is a biotechnology company dedicated to developing high-efficacy cell therapies for incurable diseases. The company specializes in next-generation allogeneic and mesenchymal stem cell (MSC) therapeutics. Its core competency lies in its proprietary Subfractionation Culturing Method, a source technology for isolating and culturing high-purity, high-potency stem cells. The R&D pipeline focuses on treating immunological and inflammatory conditions, such as graft-versus-host disease and atopic dermatitis. The company's strategy includes global expansion through mergers and acquisitions, fostering open innovation in iPSC and tissue engineering, and developing cost-effective mass production capabilities with 3D bioreactor technology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
M&A Activity
주요사항보고서(회사합병결정)
Korean 93.1 KB
2025-09-17 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.7 KB
2025-09-15 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제1회차 CB)
Korean 6.2 KB
2025-09-15 00:00
M&A Activity
합병등종료보고서(자산양수도)
Korean 15.4 KB
2025-09-08 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 47.9 KB
2025-09-08 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 59.2 KB
2025-09-05 00:00
M&A Activity
주요사항보고서(타법인주식및출자증권양수결정)
Korean 34.0 KB
2025-09-05 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 51.5 KB
2025-09-02 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 147.7 KB
2025-09-02 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 52.5 KB
2025-09-01 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 85.3 KB
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-08-14 00:00
Capital/Financing Update
타인에대한담보제공결정
Korean 20.2 KB
2025-08-08 00:00
Capital/Financing Update
타인에대한담보제공결정
Korean 19.4 KB

Automate Your Workflow. Get a real-time feed of all SCM Lifescience Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SCM Lifescience Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SCM Lifescience Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.